信迪利单抗治疗复发或难治性经典型霍奇金淋巴瘤的安全性和活性(ORIENT-1):一项多中心、单臂、2期试验
这项在中国18家医院开展的持续进行、单臂、2期研究纳入96例经两线及以上治疗后复发或难治的经典型霍奇金淋巴瘤患者,给予信迪利单抗200 mg每3周一次静脉输注。全分析集92例中74例(80.4%;95% CI 70.9-88.0)经独立影像学评审委员会评估达到客观缓解,中位随访10.5个月;89例(93%)发生治疗相关不良事件,17例(18%)发生3或4级治疗相关不良事件。作者认为信迪利单抗可能成为中国复发或难治性经典型霍奇金淋巴瘤的新治疗选择。
要点
- 全分析集92例中74例(80.4%;95% CI 70.9-88.0)经独立影像学评审委员会评估达到客观缓解。
- 96例中89例(93%)发生治疗相关不良事件,17例(18%)发生3或4级治疗相关不良事件。
- 作者认为信迪利单抗可能成为中国复发或难治性经典型霍奇金淋巴瘤的新治疗选择。
核心结论
- 作者认为,信迪利单抗可能成为中国复发或难治性经典型霍奇金淋巴瘤患者的新治疗选择。
研究设计与样本
- 这是一项正在进行的多中心、单臂、2期研究,从中国18家医院招募经组织病理学诊断、经两线及以上治疗后复发或难治的经典型霍奇金淋巴瘤患者。
- 患者接受信迪利单抗200 mg静脉给药,每3周一次,直至疾病进展、死亡、不可接受的毒性或撤回知情同意。
- 主要结局为全分析集(即经中心病理实验室确认的经典型霍奇金淋巴瘤患者)中在末例患者入组后24周内经独立影像学评审委员会(IRRC)评估达到客观缓解的患者比例。
- 2017年4月19日至2017年11月1日期间共入组96例患者并开始治疗,其中4例诊断未获中心病理实验室确认而被排除出全分析集,10例停止治疗。
主要发现
- 中位随访时间为10.5个月。
- 全分析集92例中,74例(80.4%;95% CI 70.9-88.0)在2018年4月16日分析截止日期前经IRRC评估达到客观缓解。
- 96例中89例(93%)发生治疗相关不良事件,17例(18%)发生3或4级治疗相关不良事件,最常见为发热(3例[3%])。
- 14例(15%)发生任何原因导致的严重不良事件;研究期间无患者死亡。
关键数值与推荐
- 肿瘤缓解通过增强CT扫描或MRI评估,评估时间点为基线、第6周、第15周、第24周,第24至48周期间每12周一次,第48周以后每16周一次。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD-1 and its ligands. We aimed to assess the activity and safety profile of sintilimab in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. METHODS: In this ongoing, single-arm, phase 2 study, we recruited patients with histopathologically diagnosed classical Hodgkin lymphoma that was relapsed or refractory after two or more lines of therapy from 18 hospitals in China. Patients were given intravenous sintilimab (200 mg, once every 3 weeks) until progression, death, unacceptable toxicity, or withdrawal of consent. The primary outcome was the proportion of patients in the full analysis set (ie, those with classical Hodgkin lymphoma confirmed by the central pathology laboratory) who had an objective response, as assessed by an independent radiological review committee (IRRC), by 24 weeks after enrolment of the last patient. Tumour response was assessed by enhanced CT scan or MRI at baseline, at weeks 6, 15, and 24, every 12 weeks from weeks 24 to 48, and every 16 weeks beyond week 48. Safety was assessed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT03114683, and is ongoing. FINDINGS: Between April 19, 2017, and Nov 1, 2017, 96 patients were enrolled and commenced treatment. Four patients, whose diagnosis was not subsequently confirmed by the central pathology laboratory, were excluded from the full analysis set. Ten patients discontinued treatment. Median duration of follow-up was 10·5 months. In the full analysis set (n=92), 74 patients (80·4%; 95% CI 70·9-88·0) had an IRRC-assessed objective response before the analysis cutoff date of April 16, 2018. 89 (93%) of 96 patients had treatment-related adverse events, and 17 patients (18%) had grade 3 or 4 treatment-related adverse events, the most common being pyrexia (three [3%] patients). 14 (15%) patients had serious adverse events of any cause. No patient died during the study. INTERPRETATION: Sintilimab could be a new treatment option for patients with relapsed or refractory classical Hodgkin lymphoma in China. FUNDING: Innovent Biologics, Eli Lilly and Company, National New Drug Innovation Programme, and the National Key Scientific Programme Precision Medicine Research Fund of China.
引用
- Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019. PMID: 30612710. doi:10.1016/S2352-3026(18)30192-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。